Manning Paul B
SEC-identified person · CIK 1494695 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Candel Therapeutics, Inc. CADL | Director | filed 2021 - 2026 |
| Liquidia Corp LQDA | Director | filed 2020 - 2026 |
| Verrica Pharmaceuticals Inc. VRCA | Director | filed 2018 - 2025 |
| Taysha Gene Therapies, Inc. TSHA | Director | filed 2020 - 2025 |
| Pasithea Therapeutics Corp. KTTA | Officer | filed 2023 - 2023 |
| Acumen Pharmaceuticals, Inc. ABOS | Officer | filed 2021 - 2021 |
| Dova Pharmaceuticals, Inc. DOVA | Director | filed 2017 - 2019 |
| Avexis, Inc. AVXS | Director | filed 2016 - 2018 |
| Perrigo CO PRGO | EVP & General Manager, PBM | filed 2010 - 2010 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.